Clinical Overview > Condition/ Syndrome > Lung metastases

You are looking at 1 - 3 of 3 items

Taisuke Uchida Department of Neurology, Respirology, Endocrinology and Metabolism, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan

Search for other papers by Taisuke Uchida in
Google Scholar
PubMed
Close
,
Hideki Yamaguchi Department of Neurology, Respirology, Endocrinology and Metabolism, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan

Search for other papers by Hideki Yamaguchi in
Google Scholar
PubMed
Close
,
Kazuhiro Nagamine Department of Neurology, Respirology, Endocrinology and Metabolism, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan

Search for other papers by Kazuhiro Nagamine in
Google Scholar
PubMed
Close
,
Tadato Yonekawa Department of Neurology, Respirology, Endocrinology and Metabolism, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan

Search for other papers by Tadato Yonekawa in
Google Scholar
PubMed
Close
,
Eriko Nakamura Department of Diagnostic Pathology, University of Miyazaki Hospital, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan

Search for other papers by Eriko Nakamura in
Google Scholar
PubMed
Close
,
Nobuhiro Shibata Department of Clinical Oncology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan

Search for other papers by Nobuhiro Shibata in
Google Scholar
PubMed
Close
,
Fumiaki Kawano Division of the Gastrointestinal, Endocrine and Pediatric Surgery, Department of Surgery, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan

Search for other papers by Fumiaki Kawano in
Google Scholar
PubMed
Close
,
Yujiro Asada Department of Diagnostic Pathology, University of Miyazaki Hospital, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan

Search for other papers by Yujiro Asada in
Google Scholar
PubMed
Close
, and
Masamitsu Nakazato Department of Neurology, Respirology, Endocrinology and Metabolism, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan

Search for other papers by Masamitsu Nakazato in
Google Scholar
PubMed
Close

Summary

We report a case of rapid pleural effusion after discontinuation of lenvatinib. A 73-year-old woman was diagnosed with poorly differentiated thyroid cancer with right pleural metastasis. Weekly paclitaxel treatment was performed for 18 weeks, but it was not effective. Oral administration of lenvatinib, a multi-target tyrosine kinase inhibitor, reduced the size of cervical and thoracic tumors and lowered serum thyroglobulin levels. Lenvatinib was discontinued on day 28 because of Grade 2 thrombocytopenia and Grade 3 petechiae. Seven days after discontinuation of lenvatinib, the patient was hospitalized because of dyspnea and right pleural effusion. Pleural effusion rapidly improved with drainage and re-initiation of lenvatinib and did not recur. Anorexia caused by lenvatinib led to undernutrition, which resulted in death 13 months after initiation of lenvatinib. Autopsy revealed extensive necrosis with primary and metastatic lesions, suggesting that the patient responded to lenvatinib. Physicians should be aware of the possibility of flare-up in patients with thyroid cancer treated with lenvatinib.

Learning points:

  • Autopsy findings revealed that lenvatinib was efficacious in treating poorly differentiated thyroid cancer without primary lesion resection.

  • Flare-up phenomenon may occur in thyroid cancer treated with lenvatinib.

  • Attention should be paid to flare-up phenomenon within a few days of discontinuing lenvatinib.

Open access
Whitney L Stuard Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, Texas, USA

Search for other papers by Whitney L Stuard in
Google Scholar
PubMed
Close
,
Bryan K Gallerson Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, Texas, USA

Search for other papers by Bryan K Gallerson in
Google Scholar
PubMed
Close
, and
Danielle M Robertson Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, Texas, USA

Search for other papers by Danielle M Robertson in
Google Scholar
PubMed
Close

Summary

The use of in vivo confocal microscopy (IVCM) is rapidly emerging as an important clinical tool to evaluate changes in corneal sensory nerves as a surrogate measure for diabetic peripheral neuropathy. Commonly used metrics to document and grade the severity of diabetes and risk for diabetic peripheral neuropathy include nerve fiber length, density, branching and tortuosity. In addition to corneal nerves, thinning of the retinal fiber layer has been shown to correlate with the severity of diabetic disease. Here, we present a case report on a pre-diabetic 60-year-old native American woman with abnormal corneal nerve morphology and retinal nerve fiber layer thinning. Her past medical history was positive for illicit substance abuse. IVCM showed a decrease in nerve fiber density and length, in addition to abnormally high levels of tortuosity. OCT revealed focal areas of reduced retinal nerve fiber layer thickness that were asymmetric between eyes. This is the first report of abnormally high levels of tortuosity in the corneal sub-basal nerve plexus in a patient with a past history of cocaine abuse. It also demonstrates, for the first time, that illicit substance abuse can have long-term adverse effects on ocular nerves for years following discontinued use of the drug. Studies using IVCM to evaluate changes in corneal nerve morphology in patients with diabetes need to consider a past history of illicit drug use as an exclusionary measure.

Learning points:

  • Multiple ocular and systemic factors can impede accurate assessment of the corneal sub-basal nerve plexus by IVCM in diabetes.

  • Although current history was negative for illicit substance abuse, past history can have longstanding effects on corneal nerves and the retinal nerve fiber layer.

  • Illicit drug use must be considered an exclusionary measure when evaluating diabetes-induced changes in corneal nerve morphology and the retinal nerve fiber layer.

Open access
Liudmila Rozhinskaya Departments of Neuroendocrinology and Bone Diseases

Search for other papers by Liudmila Rozhinskaya in
Google Scholar
PubMed
Close
,
Ekaterina Pigarova Departments of Neuroendocrinology and Bone Diseases

Search for other papers by Ekaterina Pigarova in
Google Scholar
PubMed
Close
,
Ekaterina Sabanova Departments of Neuroendocrinology and Bone Diseases

Search for other papers by Ekaterina Sabanova in
Google Scholar
PubMed
Close
,
Elizaveta Mamedova Departments of Neuroendocrinology and Bone Diseases

Search for other papers by Elizaveta Mamedova in
Google Scholar
PubMed
Close
,
Iya Voronkova Departments of Pathomorphology

Search for other papers by Iya Voronkova in
Google Scholar
PubMed
Close
,
Julia Krupinova Endocrinology Research Centre, Moscow, Russia

Search for other papers by Julia Krupinova in
Google Scholar
PubMed
Close
,
Larisa Dzeranova Endocrinology Research Centre, Moscow, Russia

Search for other papers by Larisa Dzeranova in
Google Scholar
PubMed
Close
,
Anatoly Tiulpakov Department and Laboratory of Inherited Endocrine Disorders

Search for other papers by Anatoly Tiulpakov in
Google Scholar
PubMed
Close
,
Vera Gorbunova Department of Chemotherapy, Cancer Research Center, Moscow, Russia

Search for other papers by Vera Gorbunova in
Google Scholar
PubMed
Close
,
Nadezhda Orel Department of Chemotherapy, Cancer Research Center, Moscow, Russia

Search for other papers by Nadezhda Orel in
Google Scholar
PubMed
Close
,
Artur Zalian Department of Chemotherapy, Cancer Research Center, Moscow, Russia

Search for other papers by Artur Zalian in
Google Scholar
PubMed
Close
,
Galina Melnichenko Endocrinology Research Centre, Moscow, Russia

Search for other papers by Galina Melnichenko in
Google Scholar
PubMed
Close
, and
Ivan Dedov Endocrinology Research Centre, Moscow, Russia

Search for other papers by Ivan Dedov in
Google Scholar
PubMed
Close

Summary

Parathyroid carcinoma is an extremely rare disorder with little treatment options. It could be misdiagnosed in medical centers with little experience in management of such cases. Our clinical case shows that the initial misdiagnosis of a parathyroid carcinoma in a young woman has led to the development of multiple lung metastases, thus making its treatment hardly possible. Initiation of treatment with sorafenib – a multi-kinase inhibitor approved for treatment of different types of cancer but not parathyroid carcinoma – has led to a significant decrease in the size of lung metastases and has prevented the progression of hyperparathyroidism, which is usually severe in cases of parathyroid carcinoma. The detection of a germline CDC73 mutation in this patient has raised additional concerns about the necessity of periodic screening for early detection of renal, jaw and uterine lesions.

Learning points:

  • Diagnosis of parathyroid carcinoma may be challenging due to the absence of reliable diagnostic criteria. Thus, thorough histological examination is needed using immunohistochemical staining of resected tissue in suspicious cases.

  • CDC73 genetic testing should be considered in patients with parathyroid carcinoma.

  • Sorafenib may be a promising treatment of patients with parathyroid carcinoma with distant metastases.

Open access